Popular on Rezul
- Mike Dew Joins RE/MAX Platinum Realty 153
- Caring for Your Trees Over the Winter: Tips from Advanced Tree Care 119
- Halagard builds a Marketplace for Opportunity Zones to help millions of Americans 115
- PacketSled Recognized by SC Media as a Finalist for Best Computer Forensic Solution
- Podcast Shines Spotlight on Calgary Entrepreneurs
- Jonathan W. Johnson, LLC Investigating Severe Turbulence/Mechanical Issue on Delta Flight from Atlanta, Georgia to Lagos, Nigeria on Behalf of Georgia
- Global Video Management Software Market
- Dealer eProcess SEM Wins Dealer Satisfaction Award
- Florida Healthcare Law Firm Expands Real Estate Law & Global Health Legal Offerings with Addition of Attorney Amanda Bhikhari!
- Universe Holdings Builds Apartment Portfolio Around New Rams Stadium with Ninth Acquisition
Similar on Rezul
- XOV opens its doors to Asia with listing on ABCC Exchange
- Blum Telehealth teams with Medxoom to modernize Patient Engagement & Payments
- Z5 Inventory Unveils Online Medical Supplies Store
- Ocean Exchange Announces 2019 Partnership and Event in Fort Lauderdale
- National Academy of Television Arts and Sciences Southeastern Chapter Celebrates 45th Anniversary
- Forty Years of Making a Difference: Public Health Technology Company Celebrates 40 Years in Business
- JustCall launches SMS Bots for Businesses to automate customer support
- Mississauga Real Estate Board (MREB) looks to improve local agent exposure with new online platform
- JustCall launches powerful Auto Dialer for Sales & Telemarketing teams
- Wizio Captures VR Content for 5% of Boston Apartments on the September 1st Move-in
Introducing NanoSmart™ Technology: Detecting the Medication You Take From Your Breath
Rezul News/10408464
Collaboration with MetroHealth hospitals of Cleveland, Ohio sees the world's first deployment of nGageIT Digital Health's novel breath-based NanoSmart™ and NanoSensor technology for Medication Adherence.
CLEVELAND - Feb. 11, 2019 - Rezul -- NanoSmart™ technology uses nanoparticles to digitally encode the outer layer of each oral medication, turning any oral medication into a digital object that can be tracked from your breath using a smartphone . Developed under nGageIT Digital Health's NanoSmart™ Digital Medicine technology program, this enables verified, non-intrusive, real-time medication and treatment adherence monitoring to take place.
In a collaboration with MetroHealth hospitals of Cleveland, Ohio - advocates for teaching and research – nGageIT Digital Health's NanoSmart™ technology will begin clinical validation trials with MetroHealth's primary care unit, where a target of over 10,000 patients will be engaged in their treatments through nGageIT Digital Health's NanoSmart™ adherence monitoring technology and support over a 24 month period. Treatment focus will initially concentrate on Statins, HPV, and Diabetes, however additional selective areas may also include digitizing oral oncology drugs, digital medicine for hepatitis, and other areas. The product is slated to complete validation trials in 2019.
Medication non-adherence costs the US healthcare system over $300 billion and results in 125,000 premature deaths per year, with more than 1 in 5 new prescriptions going unfilled and two-thirds of patients not taking their medications as prescribed. nGageIT Digital Health's NanoSmart™ technology and their NanoSensor adherence programs can drastically improve patient outcomes through non-intrusive adherence and treatment monitoring integrated with provider care teams. The data sent to provider care in real-time allows them to customize meaningful and timely interventions to improve outcomes.
More on Rezul News
With nGageIT Digital Health, MetroHealth primary care program administrators can perform patient treatment monitoring and see when at-risk behaviors are occurring, engaging the patients and intervening to remove treatment adherence barriers. Data from the trial will be used to further develop the NanoSmart™ technology adherence platform.
This has the potential to be especially important for oral oncology drugs, where it can be very difficult positively monitor medication adherence outside the clinic at the patients home.
"The exhaled breath offers a novel frontier in medicine for the development of non-invasive digital medicine solutions for cancer that are an easily deployable Smartphone based intervention." says Dr. Jennifer Murdoch, COO and Chief Clinical Officer of nGageIT Digital Health.
"Leveraging NanoSmart™ technology in serious disease treatment programs could potentially improve outcomes for substantial numbers of cancer patients," she explains.
"We believe this cutting-edge breath-based technology may be the cornerstone to meaningfully increasing survivorship, cures, and ultimately public health. We are looking forward to the emerging clinical data, and eager to see the results from prospective clinical and real-world trials as the program progresses."
nGageIT Digital Health is also developing a related breath-based early cancer and disease detection platform that detects cancerous and other disease states from your breath at very early stages and when it is present.
More About NanoSmart™ Technology
The US pharmaceutical industry alone forfeits an estimated $250 billion annually in potential revenue due to medication non-adherence.
nGageIT Digital Health's NanoSmart™ technology can do what no medication adherence technology can by verifying medication adherence non-intrusively and in real-time through the patient's breath.
More on Rezul News
With a single breath, the device detects the unique nanoparticle "barcode" of the drug ingested. The digital biomarker is based on nGageIT Digital Health's proprietary market-leading nanoparticle encoding library.
By understand the unique breath fingerprint of the patient, nGageIT Digital Health's breath sensor technology can also distinguish if the patient ingesting the drug is the same patient that it was prescribed to. This can be an important factor in tracking Opioid drug use, reducing counterfeit tablets and reducing drug diversion.
This enables accurate reporting of real-time treatment progress, enabling program administrators to easily flag at-risk events and intervene with patients, helping them maintain treatment adherence and increase the likelihood of successful treatment completion.
"The incorporation of relevant breath based digital medicine markers allows us to unequivocally and digitally verify the point of ingestion by the patient in a seamless programmatic fashion for providers and researchers where meaningful interventions can be made." says CEO of nGageIT Digital Health, Raj Reddy.
Hospital, healthcare, and provider systems, contract research organizations, and pharmaceutical companies can utilize nGageIT Digital Health's NanoSmart™ technology in treatment and primary care applications, treatment monitoring, and clinical trials program integration and study adherence verification.
The clinical version of the test for IUO use in prospective studies is expected to launch in 2019 with the commercial version launching in 2020.
About nGageIT Digital Health
nGageIT Digital Health (www.ngageittec.com) are pioneers in the field of digital medicine encoding and sensor technology. nGageIT Digital Health is committed to making medicine smarter to improve patient engagement, enrich insights and optimize therapeutic outcomes, resulting in lower overall system costs and improved health outcomes for populations.
For further information contact:
Raj Reddy CEO
Info@ngageittec.com
for investor inquiries email
Investor@ngageittec.com
In a collaboration with MetroHealth hospitals of Cleveland, Ohio - advocates for teaching and research – nGageIT Digital Health's NanoSmart™ technology will begin clinical validation trials with MetroHealth's primary care unit, where a target of over 10,000 patients will be engaged in their treatments through nGageIT Digital Health's NanoSmart™ adherence monitoring technology and support over a 24 month period. Treatment focus will initially concentrate on Statins, HPV, and Diabetes, however additional selective areas may also include digitizing oral oncology drugs, digital medicine for hepatitis, and other areas. The product is slated to complete validation trials in 2019.
Medication non-adherence costs the US healthcare system over $300 billion and results in 125,000 premature deaths per year, with more than 1 in 5 new prescriptions going unfilled and two-thirds of patients not taking their medications as prescribed. nGageIT Digital Health's NanoSmart™ technology and their NanoSensor adherence programs can drastically improve patient outcomes through non-intrusive adherence and treatment monitoring integrated with provider care teams. The data sent to provider care in real-time allows them to customize meaningful and timely interventions to improve outcomes.
More on Rezul News
- Origami in the Garden, A Traveling Exhibition Unfolding in Three Garden Locations in 2019
- Denver Realtor Patrick Finney Launches New Website
- Diane & The Deductibles Open For The Legendary Fabulous Thunderbirds at The Canyon Club in Agoura Hills on February 23rd!
- Entrepreneur Reveals Secret Formula to Making Millions
- Scappoose Real Estate Brokers Earn Berkshire Hathaway Homeservices Global Recognition
- East Portland Real Estate Broker Earns Prestigious Award
- Huntoon Joins Expert Panel at the OAC Summit to Discuss the Effect of Shifting Demographics on Open-Air Shopping Centers
With nGageIT Digital Health, MetroHealth primary care program administrators can perform patient treatment monitoring and see when at-risk behaviors are occurring, engaging the patients and intervening to remove treatment adherence barriers. Data from the trial will be used to further develop the NanoSmart™ technology adherence platform.
This has the potential to be especially important for oral oncology drugs, where it can be very difficult positively monitor medication adherence outside the clinic at the patients home.
"The exhaled breath offers a novel frontier in medicine for the development of non-invasive digital medicine solutions for cancer that are an easily deployable Smartphone based intervention." says Dr. Jennifer Murdoch, COO and Chief Clinical Officer of nGageIT Digital Health.
"Leveraging NanoSmart™ technology in serious disease treatment programs could potentially improve outcomes for substantial numbers of cancer patients," she explains.
"We believe this cutting-edge breath-based technology may be the cornerstone to meaningfully increasing survivorship, cures, and ultimately public health. We are looking forward to the emerging clinical data, and eager to see the results from prospective clinical and real-world trials as the program progresses."
nGageIT Digital Health is also developing a related breath-based early cancer and disease detection platform that detects cancerous and other disease states from your breath at very early stages and when it is present.
More About NanoSmart™ Technology
The US pharmaceutical industry alone forfeits an estimated $250 billion annually in potential revenue due to medication non-adherence.
nGageIT Digital Health's NanoSmart™ technology can do what no medication adherence technology can by verifying medication adherence non-intrusively and in real-time through the patient's breath.
More on Rezul News
- Your Lore: The Custom Website Experience Changing How We Read
- CGI Strategies Acquires Luxury Apartment Community in Orlando, FL for $43 Million
- MTB Entertainment's "Prince of the Universe" Album by Marcus Christ to be Commercially Distributed on April 16th, 2019!
- Beacon Lake to Celebrate Lake House Launch
- Berkshire Hathaway HomeServices Florida Network Realty Names Realtor Anita Vining 2018 Top Producer
- Beacon Lake Honored at Laurel Awards
- Belize's Real Estate Boom Showcased at Cerros Sands, the Ultimate in Retirement Living
With a single breath, the device detects the unique nanoparticle "barcode" of the drug ingested. The digital biomarker is based on nGageIT Digital Health's proprietary market-leading nanoparticle encoding library.
By understand the unique breath fingerprint of the patient, nGageIT Digital Health's breath sensor technology can also distinguish if the patient ingesting the drug is the same patient that it was prescribed to. This can be an important factor in tracking Opioid drug use, reducing counterfeit tablets and reducing drug diversion.
This enables accurate reporting of real-time treatment progress, enabling program administrators to easily flag at-risk events and intervene with patients, helping them maintain treatment adherence and increase the likelihood of successful treatment completion.
"The incorporation of relevant breath based digital medicine markers allows us to unequivocally and digitally verify the point of ingestion by the patient in a seamless programmatic fashion for providers and researchers where meaningful interventions can be made." says CEO of nGageIT Digital Health, Raj Reddy.
Hospital, healthcare, and provider systems, contract research organizations, and pharmaceutical companies can utilize nGageIT Digital Health's NanoSmart™ technology in treatment and primary care applications, treatment monitoring, and clinical trials program integration and study adherence verification.
The clinical version of the test for IUO use in prospective studies is expected to launch in 2019 with the commercial version launching in 2020.
About nGageIT Digital Health
nGageIT Digital Health (www.ngageittec.com) are pioneers in the field of digital medicine encoding and sensor technology. nGageIT Digital Health is committed to making medicine smarter to improve patient engagement, enrich insights and optimize therapeutic outcomes, resulting in lower overall system costs and improved health outcomes for populations.
For further information contact:
Raj Reddy CEO
Info@ngageittec.com
for investor inquiries email
Investor@ngageittec.com
Source: nGageIT Digital Health
Filed Under: Healthcare, Technology
0 Comments
Latest on Rezul News
- John R. Wood Announces Top Producers for January 2019
- Tenant E-Signatures for Faster and Easier Tenant Enrollments
- New Market Report: Industry 4.0 Market, Technologies & Industry 2019-2023
- New Models from The Pioneer Collection at Adonea Grand Open February 23rd and 24th!
- O'Dwyer Homes is Atlanta's Only Local Energy Star Certified Builder
- Z5 Inventory Unveils Online Medical Supplies Store
- BREAK UP! WITH YOUR RENTAL: The Professional Woman's Guide To Building Wealth Through Real Estate
- Porous Pave, Inc. Names Matt R. Lamb as Vice President, Sales and Marketing
- IAWP Wellness Coach Certification Program Awarded CCE Accreditation By The International Coach Federation
- Former CEO of Procter & Gamble Brazil Joins CEO Coaching International
- The industry versus its yachtowners
- Advanced Tree Care Offers Nighttime Commercial Tree Trimming
- Maxx Marketing Names George Funk as Vice President, Sales Effective February 5, 2019
- Garden City Realty recognizes its January Agents of the Month
- Tokara Homebuilder CRM, Powered by Pivotal Announces Launch of Complete Homebuilder CRM Solution
- DMS Honors Nation's Defenders And First Responders With First-Ever DMS Heroes & Legends Ultramarathon
- TrailMark and GreyHawk Honored at Laurel Awards
- Toll Brothers to build new community in Timnath
- The Best Time to Buy a Belize Beach House? Right Now!
- Ashlyn Derosier Joins The Pro's Real Estate Team